Mereo BioPharma signs option-and-license deal with Sentynl for US rights to alvelestat in AATD lung disease

• Mereo BioPharma entered an option and license deal with Sentynl for alvelestat in AATD-associated lung disease, covering U.S. commercialization rights.
• Sentynl secured global manufacturing rights; Mereo retained commercial rights outside the U.S. under the agreement.
• Mereo will collect a non-refundable option fee; option exercise triggers USD 40 million upfront and R&D payments.
• Deal includes up to USD 435 million in milestones; Mereo also gets double-digit tiered royalties on U.S. net sales.
• Mereo will lead global Phase 3 development; program could start in early 2027, with both sides refining trial design during the option period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110800PRIMZONEFULLFEED9807652) on August 11, 2026, and is solely responsible for the information contained therein.